VanEck Video Gaming and eSports ETF vs Cassava Sciences Inc — how do they compare? VanEck Video Gaming and eSports ETF trades at $99.92 (market cap $248.06M), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: VanEck Video Gaming and eSports ETF is far larger — about 6.3× Cassava Sciences Inc's market cap, and VanEck Video Gaming and eSports ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 66 Days and Cassava Sciences Inc for 37 Days on average.
| ESPO | FLNA | |
|---|---|---|
Market Cap | $248.06M | $39.40M |
Volume | 13,622 | 759,018 |
Sector | Sector/Thematic | Health |
52-Week High | $118.68 | $4.64 |
52-Week Low | $85.25 | $0.68 |
Typical Hold Time | 66 Days | 37 Days |
Enterprise Value | — | -$43.28M |
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $97.32, down 0.33% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $97 and resistance at $98. Financial ratios are unavailable in the provided data, limiting fundamental insight. No recent news is available to drive sentiment.
The outlook is mixed: technicals suggest upward momentum, but the absence of fundamental data and recent news creates uncertainty. Risks include market volatility and lack of visibility on financial health. Investors need updated earnings and guidance for a clearer investment case.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →